Correspondence 0001193125-23-275752 from Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc.
Date: Nov. 13, 2023 · CIK: 0001636651 · Accession: 0001193125-23-275752
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275307
Letter
OVID THERAPEUTICS INC.
441 9th Ave 14th Floor
New York, NY 10001
November 13, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Tim Buchmiller
Re:
Ovid Therapeutics Inc.
Registration Statement on Form S-3 (File No. 333-275307)
Request for Acceleration of Effective Date
Mr. Buchmiller:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-275307) (the “Registration Statement”) to become effective on November 15, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff.
Once the Registration Statement has been declared effective, please orally confirm the event with Jaime Chase of Cooley LLP, counsel to the Registrant, at (202) 728-7096 or by e-mail at jchase@cooley.com.
[Signature page follows]
Very truly yours,
Ovid Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP OVID THERAPEUTICS INC. 441 9th Ave 14th Floor New York, NY 10001 November 13, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Ovid Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-275307) Request for Acceleration of Effective Date Mr. Buchmiller: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-275307) (the “Registration Statement”) to become effective on November 15, 2023, at 4:00 p.m. Eastern Time, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff. Once the Registration Statement has been declared effective, please orally confirm the event with Jaime Chase of Cooley LLP, counsel to the Registrant, at (202) 728-7096 or by e-mail at jchase@cooley.com. [Signature page follows] Very truly yours, Ovid Therapeutics Inc. By: /s/ Thomas M. Perone Thomas M. Perone General Counsel, Corporate Secretary and Chief Compliance Officer cc: Jeremy M. Levin, Ovid Therapeutics Inc. Jeffery Rona, Ovid Therapeutics Inc. Laura Berezin, Cooley LLP Jaime Chase, Cooley LLP Signature Page to Company Acceleration Request – S-3 2023